| http://www.w3.org/ns/prov#value | - The two companies say development funding by Mundipharma will also support jointly agreed-upon clinical development activities including but not limited to planned Phase III studies in previously undiagnosed PTCL and in combination with bexarotene in relapsed or refractory cutaneous T-cell lymphoma (CTCL).
|
